Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

The labeling for Otezla (apremilast; Amgen) has been updated to include safety and efficacy information related to the treatment of patients with moderate to severe plaque psoriasis of the scalp. The ...

Guselkumab demonstrated strong efficacy in treating moderate to severe scalp psoriasis, especially in individuals with skin of color, achieving nearly 70% complete scalp clearance by week 48. The ...

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported health-related quality of life outcomes in people of color. Guselkumab shows rapid and significant ...

People of color with scalp psoriasis experienced significant improvement in scalp itch and patient-reported health-related quality-of-life outcomes. Guselkumab (Tremfya) showed rapid and significant ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Deucravacitinib maintained efficacy and safety when ...

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

When you first notice the telltale signs of scalp psoriasis, you might think you actually have dandruff. After all, scalp psoriasis may cause itching and white flakes, just like dandruff. Despite the ...